Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Adalimumab in Ankylosing Spondylitis
NCT05527444Phase 4Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab in ankylosing spondylitis (AS) (4 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Ankylosing Spondylitis Disease Activity Score at 12 weeks. Status: unknown.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05527444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527444.